Jason Luke, MD, FACP, is an associate professor of medicine in the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine and the director of the Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Center Immunology and Immunotherapy Program discusses A phase I, first-in-human, open-label, dose-escalation study of MGD013.
A phase I, first-in-human study of MGD013 -What do we need to know about MGD013 – Jason Luke MD FACP – UPMC Hillman Cancer Center Immunology @jasonlukemd @UPMCHillmanCC @PittTweet #immuno…
